-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – AM-1476 in Idiopathic Pulmonary Fibrosis
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - AM-1476 in Idiopathic Pulmonary Fibrosis report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. AM-1476 in Idiopathic Pulmonary Fibrosis Drug Details: AM-1476 is under development...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Bersiporocin in Idiopathic Pulmonary Fibrosis
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Bersiporocin in Idiopathic Pulmonary Fibrosis report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Bersiporocin in Idiopathic Pulmonary Fibrosis Drug Details: Bersiporocin (DWN-12088, DWJ-209) is...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – (Avibactam + Aztreonam) in Bacterial Pneumonia
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - (Avibactam + Aztreonam) in Bacterial Pneumonia report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. (Avibactam + Aztreonam) in Bacterial Pneumonia Drug Details: PF-06947387 (aztreonam...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Eblasakimab in Atopic Dermatitis (Atopic Eczema)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Eblasakimab in Atopic Dermatitis (Atopic Eczema) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Eblasakimab in Atopic Dermatitis (Atopic Eczema) Drug Details: eblasakimab (ASLAN-004)...
-
Product Insights
Liver Cirrhosis – Drugs In Development, 2023
Global Markets Direct’s, ‘Liver Cirrhosis - Drugs In Development, 2023’, provides an overview of the Liver Cirrhosis pipeline landscape. The report provides comprehensive information on the therapeutics under development for Liver Cirrhosis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...
-
Product Insights
Hypophosphatasia – Drugs In Development, 2023
Global Markets Direct’s, ‘Hypophosphatasia - Drugs In Development, 2023’, provides an overview of the Hypophosphatasia pipeline landscape. The report provides comprehensive information on the therapeutics under development for Hypophosphatasia, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key...
-
Product Insights
Colitis – Drugs In Development, 2023
Global Markets Direct’s, ‘Colitis - Drugs In Development, 2023’, provides an overview of the Colitis pipeline landscape. The report provides comprehensive information on the therapeutics under development for Colitis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Ferroquine in Malaria
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.Ferroquine in Malaria Drug Details:Ferroquine is under development for the treatment of uncomplicated Plasmodium falciparum malaria....
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – OLX-301A in Wet (Neovascular / Exudative) Macular Degeneration
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.OLX-301A in Wet (Neovascular / Exudative) Macular Degeneration Drug Details:OLX-301A is under development for the treatment...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Arsenic Trioxide in Chronic Myelomonocytic Leukemia (CMML)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Arsenic Trioxide in Chronic Myelomonocytic Leukemia (CMML) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.Arsenic Trioxide in Chronic Myelomonocytic Leukemia (CMML) Drug Details:Arsenic trioxide...